Med Uni Graz and Boehringer Ingelheim Open Lung Cancer Research Lab

The Medical University of Graz and Boehringer Ingelheim have opened a Christian Doppler Laboratory dedicated to developing new therapies for non-small cell lung cancer, with a specific focus on immunogenic cell death.¹ The 7-year program, funded at €3.2 million (US$3.7 million) split equally between Boehringer Ingelheim and public funding bodies, represents a structured attempt to close one of oncology's most persistent gaps, durable response rates in a disease that remains the leading cause of cancer-related deaths worldwide.

The research agenda here is notable for its specificity.¹ Rather than pursuing broad immunotherapy mechanisms, the laboratory is targeting the upstream biology that determines whether a tumor is visible to the immune system at all.

Why Does Immunogenic Cell Death Matter for Drug Development?

Cells in the human body have a natural self-destruct program.¹ When damaged or no longer needed, they die in a controlled manner a process essential to maintaining the body's health. In certain cases, known as immunogenic cell death, dying cells emit signals that actively recruit immune cells to potential threats. In non-small cell lung cancer, these mechanisms are frequently suppressed, allowing tumors to proliferate undetected.

"In non-small cell lung cancer, these mechanisms are often switched off. As a result, the tumor can grow undetected by the immune system,"¹ explained Philipp Jost, director of the Division of Oncology, Medical University of Graz, in a press release.

"The aim of our research is therefore to influence cancer cells in such a way that they can be more easily recognized and attacked by the immune system. If successful, existing cancer therapies could become significantly more effective,”¹ noted Michael Dengler, co-lead, Christian Doppler Laboratory, in the press release.

The hypothesis is not that a new molecule replaces existing therapies, but that restoring immunogenic signaling could meaningfully extend the utility of treatments already in clinical use, including targeted therapies and immunotherapies that currently offer only temporary benefit before relapse.¹

What Does This Mean for Translational Pipeline Strategy?

The laboratory's structure is designed specifically to accelerate the journey from mechanistic insight to clinical application.¹ Located on the Medical University of Graz campus within Medical Science City Graz, the lab has access to clinically relevant samples through Biobank Graz, providing the kind of human-derived data that often proves the critical bottleneck in early translational work.

Boehringer Ingelheim, which coordinates its global oncology research from Austria through its Regional Center Vienna, a site focused on cancer biology, computational innovation, and translational research, brings industry-side development expertise to the collaboration.¹ "This partnership brings together complementary strengths: the scientific excellence and clinical integration of Med Uni Graz and our expertise in the discovery and development of new cancer therapies. Together, we aim to accelerate the development of treatments that have the potential to sustainably change the course of the disease,"¹ said Mark Paul Petronczki, head of Oncology Research, Boehringer Ingelheim, in the press release.

The laboratory's leads describe their core work as investigating the biological mechanisms that determine how and when lung cancer cells die.¹ This means the near-term outputs are likely to be mechanistic data and validated biological targets, rather than late-stage candidates. The program is structured to move findings toward clinical application with an industry partner already positioned to act on them.

Andrea Kurz, rector, Medical University of Graz, framed the intent, in the press release,¹ "Through our partnership with Boehringer Ingelheim, we are strengthening our ability to translate new scientific insights into transformative therapeutic approaches for patients. This Christian Doppler Laboratory provides an outstanding framework to connect basic research with clinical application and to accelerate innovation where it is needed most."

The Christian Doppler Research Association model is a well-established Austrian mechanism for this kind of public-private research collaboration. Federal Minister Wolfgang Hattmannsdorfer, noted, in the press release,¹ "This Christian Doppler Laboratory is a prime example of how successful innovation policy works: when science and industry collaborate closely, innovation, value creation, and high-quality jobs emerge."

What Are the Other Notable Developments in Med Uni Graz?

Separate research may carry implications for how the field approaches cell detection more broadly.² A team at the Medical University of Graz has published findings on microchimerism including the first successful application of a new technology for detecting extremely rare cells. "Now that we are able to detect these cells more directly, sensitively and reliably, new opportunities in research and diagnostics are opening up," said Thomas Kroneis, project leader of the Division of Cell Biology, Histology and Embryology at the Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Med Uni Graz, in a press release.² The methodology, developed in part through a $5.34 million John Templeton Foundation grant, may have downstream applications in cancer research and diagnostics.

References

1. Medical University of Graz. Med Uni Graz and Boehringer Ingelheim open new Christian Doppler Laboratory. Published March 17, 2026. Accessed March 17, 2026. https://www.medunigraz.at/en/news/detail/medizinische-universitaet-graz-und-boehringer-ingelheim-eroeffnen-neues-christian-doppler-labor
2. Medical University of Graz. Neue Einblicke in den Mikrochimärismus vorgestellt. Published March 4, 2026. Accessed March 17, 2026. https://www.medunigraz.at/en/news/detail/neue-einblicke-in-den-mikrochimaerismus-grazer-forschung-setzt-internationale-massstaebe